Humacyte Inc (HUMA)

[buccaneer1961]

Just a bit....lololozzzzz

[TrendTrade2016]

Off by 1c…. I need to study harder I guess.

[buccaneer1961]

Perfectly

[TrendTrade2016]

HUMA READY FOR 3.96 Target....PRECISION TA!!!!

[TrendTrade2016]

HUMA let’s see that target hit today. Red market coming up

[buccaneer1961]

Awesome!

[TrendTrade2016]

HUMA...BREAKING 3.83 RESISTANCE

[TrendTrade2016]

HUMA DRIVING OUT OF THE GATE

[TrendTrade2016]

Daily 50x200 cross takes it to 5 bucks

[TrendTrade2016]

HUMA 3.77 trigger sends it to 3.96

[TrendTrade2016]

U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Humacyte’s Biologics License Application (BLA)

[TrendTrade2016]

HUGE.... developing universally implantable, bioengineered human tissue

[TrendTrade2016]

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

[buccaneer1961]

That's worth a lot

[TrendTrade2016]

Yup. One positive PR will pop it. Looks like they have finished one phase 3
One for vascular war time trauma which would eliminate amputation

[buccaneer1961]

Hopefully FDA likes what they see in the fastback review

[buccaneer1961]

Ok..so no phases..looks promising here got only 100 shares

[TrendTrade2016]

HUMA MONSTER

[TrendTrade2016]

CAN'T ANSWER THAT..ITS NOT A DRUG...READ UP/////Humacyte’s platform technology has the potential to change the lives of countless people around the world by overcoming the current limitations in existing standards of care. We are leveraging our scalable technology platform to develop bioengineered human tissues for use in the treatment of diseases and conditions across a wide range of clinical needs. We are initially using our technology to bioengineer and manufacture the Human Acellular Vessel™, or HAV™, to address the significant unmet needs across multiple potential indications in vascular repair, reconstruction and replacement. The HAV is currently being investigated across multiple clinical trials in vascular trauma, AV access for hemodialysis, and peripheral arterial disease. Our pipeline vision is to evolve the utility of the HAV technology and develop future opportunities for coronary artery bypass grafting, pediatric heart surgery, the delivery of cellular therapies- including transplant of islet cells to treat Type 1 diabetes patients.

Humacyte has successfully developed the Human Acellular Vessel (HAV) from concept to wholly owned commercial-scale production in our manufacturing facilities, which have the capacity to provide thousands of vessels for treating patients in need. The HAV is created through a precise process involving the three major steps.

[buccaneer1961]

When will they know if it's approved?

[TrendTrade2016]

HUMA READY TO BLOW UP...FDA ON THE HORIZON...LOVE THE TECH HERE

[Notademoc]

So quite out there

[Notademoc]

Just bought a few shares… lets see how this goes

[Glider549]

Piper Sandler price target, $17

[Glider549]

YEP!
$$$

[nsomniyak]

Anyone else here in HUMA?